A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
This clinical trial is testing whether taking two targeted cancer drugs together is better than taking just one. Researchers want to see if this combination can help shrink or slow down the growth of certain solid tumors that have a specific protein called HER2.
You might be able to join if you have a solid tumor (other than breast cancer) with high levels of the HER2 protein. Your eligibility will also depend on specific genetic test results from your tumor.
Participants will take targeted cancer therapy pills, either alone or in combination. You will also have regular check-ups, which include imaging scans, heart tests, and tissue or fluid samples to monitor your health.
This study is currently recruiting patients and takes place at multiple locations across the United States, including in Alabama and Alaska.
- 1Tests targeted cancer drugs to block signals that help cancer grow
- 2Open to patients with certain HER2-positive solid tumors, excluding breast cancer
- 3Involves regular check-ups, scans, and heart monitoring for your safety
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.